Coya Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 Coya Therapeutics, Inc. Delaware(State or other jurisdiction ofincorporation or organization)5850 San Felipe St., Suite 500Houston, TX(Address of principal executive offices)Registrant’s telephone number, including area code: (800) 587-8170 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and Large accelerated filerNon-accelerated filerEmerging growthcompany If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒The number of shares of Registrant’s common stock outstanding as of May 8, 2026 was 23,457,183. Table of Contents PART IFinancial Information Item 1.Financial Statements 3 Condensed Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025Condensed Unaudited Interim Statements of Operations for the Three Months Ended March 31, 2026 and 2025Condensed Unaudited Interim Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026and 2025Condensed Unaudited Interim Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025Notes to the Condensed Unaudited Interim Financial Statements Item 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART IIOther Information31 Part I – Financial Information COYA THERAPEUTICS, INC.CONDENSED BALANCE SHEETS Per share information: COYA THERAPEUTICS, INC.NOTES TO CONDENSED UNAUDITED INTERIM FINANCIAL STATEMENTS 1. Organization and description of business Coya Therapeutics, Inc. (“Coya”, or the “Company”) is a clinical-stage biotechnology company focused on developingproprietary new therapies to enhance the function of Regulatory T cells (“Tregs”). Coya’s initial developmental programs arefocused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Going concern and liquidity The Company has incurred losses since inception, negative cash flows from operations and has an accumulated deficit of$69.2 million as of March 31, 2026. The Company anticipates incurring additional losses until such time, if ever, that it cangenerate significant sales of its product candidates currently in development. Substantial additional financing will be needed by the TheCompany follows the provisions of Financial Accounting Standards Board(“FASB”)Accounting StandardsCodification (“ASC”) Topic 205-40, Presentation of Financial Statements—Going Concern, which requires management toevaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’sability to continue as a going concern for one year after the date that the financial statements are issued (or when applicable, oneyear after the date that the financial statements are available to be issued). The Company's cash and cash equivalents of $50.7 The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realizationof assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments Risks and uncertainties The Company is subject to a number of risks associated with companies at a similar stage, including dependence on keyindividuals, competition from similar products and larger companies, volatility of the industry, ability to obtain adequate financing 2. Basis of presentation and significant accounting policies Basis of presentation The accompanying financial statements have been prepared in conformity with U.S. generally accepted accountingprinciples (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and In the opinion of management, the accompanying condensed un